3- ((2- benzyl- 6- (3- methoxypropyloxy)pyridin- 3- yl)ethynyl)quinuclidin- 3- ol

an orally active squalene synthase inhibitor for treating Chagas' disease; structure in first source

Also Known As:

(3R)-3-((2-benzyl-6-(3-methoxypropyloxy)pyridin-3-yl)ethynyl)quinuclidin-3-ol; ER 119884; ER-119884; ER119884

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Caldera, Aura: 2 articles (11/2008 - 07/2004)
2.	Concepcion, Juan Luis: 2 articles (11/2008 - 07/2004)
3.	Urbina, Julio A: 2 articles (11/2008 - 07/2004)
4.	Fernandes Rodrigues, Juliany Cola: 1 article (11/2008)
5.	Rodrigues, Carlos: 1 article (11/2008)
6.	de Souza, Wanderley: 1 article (11/2008)
7.	Hiyoshi, Hironobu: 1 article (07/2004)
8.	Otomo, Takeshi: 1 article (07/2004)
9.	Payares, Gilberto: 1 article (07/2004)
10.	Sanoja, Cristina: 1 article (07/2004)

1.	Parasitemia 07/01/2004 - "In vivo studies indicated that E5700 was able to provide full protection against death and completely arrested the development of parasitemia when given at a concentration of 50 mg/kg of body weight/day for 30 days, while ER-119884 provided only partial protection. "
2.	Body Weight (Weight, Body) 07/01/2004 - "In vivo studies indicated that E5700 was able to provide full protection against death and completely arrested the development of parasitemia when given at a concentration of 50 mg/kg of body weight/day for 30 days, while ER-119884 provided only partial protection. "
3.	Cutaneous Leishmaniasis 11/01/2008 - "ER-119884 and E5700, novel arylquinuclidine derivatives developed as cholesterol-lowering agents, were potent in vitro growth inhibitors of both proliferative stages of Leishmania amazonensis, the main causative agent of cutaneous leishmaniasis in South America, with the 50% inhibitory concentrations (IC(50)s) being in the low-nanomolar to subnanomolar range. "